Artiva Biotherapeutics issues Q2 2026 results release

Artiva Biotherapeutics, Inc. reported that on August 6, 2026 it issued a press release announcing its financial results for the quarter ended June 30, 2026.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. reported that on August 6, 2026 it issued a press release announcing its financial results for the quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and describes the company’s performance for that period.

The company explains that the information in this financial results press release, including Exhibit 99.1, is being furnished under the Exchange Act and is not deemed “filed” for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act documents unless expressly stated. Artiva’s common stock trades on the Nasdaq Global Market under the symbol ARTV, and it is identified as an emerging growth company.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Emerging growth company, Section 18 of the Securities Exchange Act of 1934, incorporated by reference, Inline XBRL

4 terms

Emerging growth company regulatory

"Emerging growth company status under Rule 405 of this chapter"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 18 of the Securities Exchange Act of 1934 regulatory

"shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934"

incorporated by reference regulatory

"nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Earnings Snapshot

quarter ended June 30, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Artiva Biotherapeutics (ARTV) announce on August 6, 2026?

Artiva Biotherapeutics announced that it issued a press release reporting its financial results for the quarter ended June 30, 2026, and made that press release available as Exhibit 99.1 under the Exchange Act.

Which period do the ARTV financial results relate to?

The reported financial results for Artiva Biotherapeutics relate to the quarter ended June 30, 2026. The company describes this period in a press release furnished as Exhibit 99.1 in connection with its current disclosure.

How did Artiva Biotherapeutics (ARTV) provide its Q2 2026 financial results?

Artiva Biotherapeutics provided its Q2 2026 financial results through a press release dated August 6, 2026. This press release is attached as Exhibit 99.1 and is treated as information furnished under the Exchange Act.

Is Artiva Biotherapeutics’ financial results press release deemed filed with the SEC?

The company states the financial results press release, including Exhibit 99.1, is furnished, not filed for purposes of Section 18 of the Exchange Act and is not automatically incorporated into other securities law documents unless explicitly designated.

What is Exhibit 99.1 in Artiva Biotherapeutics’ (ARTV) disclosure?

Exhibit 99.1 is the press release dated August 6, 2026 that announces Artiva Biotherapeutics’ financial results for the quarter ended June 30, 2026. It contains the detailed financial information referenced in the company’s current disclosure.

On which exchange is Artiva Biotherapeutics (ARTV) listed and what is its status?

Artiva Biotherapeutics’ common stock is listed on the Nasdaq Global Market under the symbol ARTV. The company also identifies itself as an emerging growth company under applicable securities regulations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 04:10 PM Accepted by SEC EDGAR 08/06/2026 - 04:09 PM Learn about SEC filing dates

false000181724100018172412026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

Artiva Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42179		83-3614316
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5505 Morehouse Drive, Suite 100

San Diego, California 92121

(Address of principal executive offices)

Registrant’s telephone number, including area code: (858) 267-4467

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		ARTV		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless Artiva expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 6, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Artiva Biotherapeutics, Inc.
By:		/s/ Fred Aslan
		Fred Aslan, M.D.
		Chief Executive Officer

Dated: August 6, 2026

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 187.0 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 31.3 KB